Ganglioside GM3 synthase is a key enzyme involved in the biosynthesis of gangliosides. GM3 synthase deficiency (GM3D) causes an absence of GM3 and all downstream biosynthetic derivatives. The affected individuals manifest with severe irritability, intractable seizures, and profound intellectual disability. The current study is to assess the effects of an oral ganglioside supplement to patients with GM3D, particularly on their growth and development during early childhood. A total of 13 young children, 11 of them under 40 months old, received oral ganglioside supplement through a dairy product enriched in gangliosides, for an average of 34 months. Clinical improvements were observed in most children soon after the supplement was initiated. Significantly improved growth and development were documented in these subjects as average percentiles for weight, height, and occipitofrontal circumference increased in 1–2 months. Three children with initial microcephaly demonstrated significant catch-up head growth and became normocephalic. We also illustrated brief improvements in developmental and cognitive scores, particularly in communication and socialization domains through Vineland-II. However, all improvements seemed transient and gradually phased out after 12 months of supplementation. Gangliosides GM1 and GM3, although measureable in plasma during the study, were not significantly changed with ganglioside supplementation for up to 30 months. We speculate that the downstream metabolism of ganglioside biosynthesis is fairly active and the potential need for gangliosides in the human body is likely substantial. As we search for new effective therapies for GM3D, approaches to reestablish endogenous ganglioside supplies in the affected individuals should be considered.
This is a preview of subscription content, log in to check access.
We thank the families for their patience and support. We appreciate many physicians who provided outstanding and compassionate care to the children affected by the disease. The study was supported in part by Fonterra (via the New Zealand Primary Growth Partnership program, funded by Fonterra Co-operative Group Ltd and the NZ Ministry for Primary Industries) and the Zverina Family Foundation.
Supplementary Table 3Selective Vineland Adaptive Behavior Scales – Second Edition (Vineland-II) in GM3D patients receiving G500 (DOCX 20 kb)
Boccuto L, Aoki K, Flanagan-Steet H, Chen CF et al (2014) A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation. Hum Mol Genet 23:418–433CrossRefGoogle Scholar
Boukhris A, Schule R, Loureiro JL et al (2013) Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am J Hum Genet 93:118–123CrossRefGoogle Scholar
Edvardson S, Baumann AM, Mühlenhoff M et al (2013) West syndrome caused by ST3Gal-III deficiency. Epilepsia 54:e24–e27CrossRefGoogle Scholar
Farukhi F, Dakkouri C, Wang H et al (2006) Etiology of vision loss in ganglioside GM3 synthase deficiency. Ophthalmic Genet 27:89–91CrossRefGoogle Scholar
Fragaki K, Ait-El-Mkadem S, Chaussenot A et al (2013) Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. Eur J Hum Genet 21:528–534CrossRefGoogle Scholar
Gurnida DA, Rowan AM, Idjradinata P et al (2012) Association of complex lipids containing gangliosides with cognitive development of 6-month-old infants. Early Hum Dev 88:595–601CrossRefGoogle Scholar
Gustavsson M, Hodgkinson SC, Fong B et al (2010) Maternal supplementation with a complex milk lipid mixture during pregnancy and lactation alters neonatal brain lipid composition but lacks effect on cognitive function in rats. Nutr Res 30:279–289CrossRefGoogle Scholar
Huang Q, Zhou X, Liu D et al (2014) A new liquid chromatography/tandem mass spectrometry method for quantification of gangliosides in human plasma. Anal Biochem 455:26–34CrossRefGoogle Scholar
Huang Q, Liu D, Xin B et al (2016) Quantification of monosialogangliosides in human plasma through chemical derivatization for signal enhancement in LCeESI-MS. Anal Chim Acta 929:31–38CrossRefGoogle Scholar
Mitchell MD, Henare K, Balakrishnan B et al (2012) Transfer of gangliosides across the human placenta. Placenta 33:312–316CrossRefGoogle Scholar
Ohmi Y, Ohkawa Y, Tajima O et al (2014) Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord. J Neuroinflammation 11:61CrossRefGoogle Scholar
Pan XL, Izumi T (2000) Variation of the ganglioside compositions of human milk, cow’s milk and infant formulas. Early Hum Dev 57:25–31CrossRefGoogle Scholar
Schengrund CL (2015) Gangliosides: glycosphingolipids essential for normal neural development and function. Trends Biochem Sci 40:397–406CrossRefGoogle Scholar
Simpson MA, Cross H, Proukakis C et al (2004) Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet 36:1225–1229CrossRefGoogle Scholar
Wang B, McVeagh P, Petocz P et al (2003) Brain ganglioside and glycoprotein sialic acid in breastfed compared with formula-fed infants. Am J Clin Nutr 78:1024–1029CrossRefGoogle Scholar
Wang H, Bright A, Xin B et al (2013) Cutaneous dyspigmentation in patients with ganglioside GM3 synthase deficiency. Am J Med Genet 161A:875–879CrossRefGoogle Scholar
Wang H, Wang A, Wang D et al (2016) Early growth and development impairment in patients with ganglioside GM3 synthase deficiency. Clin Genet 89:625–629CrossRefGoogle Scholar
Yoo SW, Motari MG, Susuki K et al (2015) Sialylation regulates brain structure and function. FASEB J 29:3040–3053CrossRefGoogle Scholar
Yoshikawa M, Go S, Suzuki SI et al (2015) Ganglioside GM3 is essential for the structural integrity and function of cochlear hair cells. Hum Mol Genet 24:2796–2807CrossRefGoogle Scholar